课题基金 / 基金详情

The development of next-generation albumin preparation by mutagenesi s studies

The development of next-generation albumin preparation by mutagenesi s studies
诱变研究开发下一代白蛋白制剂
批准号:
14370759
负责人:
OTAGIRI Masaki
金额:
$8.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004

项目摘要

项目成果

OTAGIRI Masaki的其他基金

相似基金

相关文献

中文摘要
翻译
人血清白蛋白(HSA)具有维持渗透压、药物结合和抗氧化活性等多种维持体内平衡的重要功能。人血清白蛋白的诱变研究使得研究各种氨基酸残基和结构域参与人血清白蛋白的结合能力、抗氧化活性和延长半衰期等功能性质成为可能。在本研究中,我们首先研究了人血清白蛋白单一残基突变体的抗氧化特性。半胱氨酸残基,特别是^<166和gt;Cys对白蛋白的这一功能贡献很大。其次,利用毕赤酵母分别表达了这三个RHSA结构域。重组结构域I蛋白的抗氧化活性与重组人血清白蛋白相当。设计了一种具有潜在高抗氧化活性的新型结构域交换HSA,将HSA的三个结构域I蛋白基因融合在一起。这种交换的人血清白蛋白具有比野生型人血清白蛋白更高的抗氧化活性。第三,利用巴斯德毕赤酵母表达重组人血清白蛋白二聚体。重组人血清白蛋白二聚体的结构和结合能力与天然人血清白蛋白几乎相同。结果表明,重组人血清白蛋白二聚体具有较好的血管内滞留和较低的血管通透性。最后,单残基突变体R410C只需导入野生型即可。S-NO-R410C具有比S-NO-HSA更高的抗菌活性,本研究结果为进一步开发新型重组白蛋白提供了重要的基础数据。
英文摘要
Human serum albumin(HSA) has many essential functions for homeostasis, such as the maintenance of osmotic pressure, drug binding and antioxidant activity. Mutagenesis studies of HSA made it possible to examine the participation of various amino acid residues and domains in the functional properties of HSA, such as binding capacity, antioxidant activity and prolonged half-life.In this study, firstly, we studied the antioxidant properties of single-residue mutants of human serum albumin. Cysteine residues, especially ^<166>Cys contribute much to this function of albumin. Secondly, Pichia pastoris has been used to express each of the three rHSA domains separately. Recombinant domain I protein exhibited antioxidant activity comparable to that of rHSA. A novel domain exchange HSA with potentially high antioxidant activity was designed where three domain I proteins of HSA were genetically fused. This exchanged HSA had higher antioxidant activity than wild-type HSA. Thirdly, rHSA dimer has been expressed using Pichia pastoris. The structure and binding capacity of rHSA dimer was almost identical to that of native HSA. rHSA dimer was shown to exhibit better intravascular retention and lower vascular permeability properties. Lastly, single-residue mutants R410C efficiently introduced NO further than the wild type. S-NO-R410C had higher antibacterial activity than S-NO-HSA.The results of this research serve as important fundamental data for further development of new recombinant albumin.
期刊论文(78)
专著(0)
科研奖励(0)
会议论文
中城圭介, 小田切優樹(他4名): "The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants"Biochimica Biophysica Acta. 1623. 88-97 (2003)
Keisuke Nakagi、Yuki Odagiri(以及其他 4 人):“重组突变体揭示的糖基化对人血清白蛋白的结构、功能和生物命运的影响”Biochimica Biophysicala Acta。1623. 88-97 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
櫻井祐治, 小田切優樹(他6名): "Esterase-like activity of serum albumin : Characterization of its structural chemistry using p-nitrophenyl esters as substrates"Pharmaceutical Research. 21. 285-292 (2004)
Yuji Sakurai、Yuki Odagiri(其他 6 名):“血清白蛋白的酯酶样活性:使用对硝基苯酯作为底物表征其结构化学”Pharmaceutical Research 21. 285-292 (2004)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
安楽 誠, 小田切優樹(他5名): "Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo"Pharmaceutical Research. 20. 684-692 (2003)
Makoto Anraku、Yuki Odagiri(以及其他 5 人):“氯胺-T 诱导的人血清白蛋白氧化作为体内氧化损伤模型的验证”药物研究 20. 684-692 (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N-acetyl-L-cysteine and albumin through the formation of mixed disulfides in human and rat serum in vitro.
N-乙酰基-L-半胱氨酸与白蛋白在体外人和大鼠血清中形成混合二硫化物。
DOI: --
发表时间: 2002
期刊: Pharmaceutical Research 19
影响因子: --
作者: [Harada D, Naito S, Otagiri M.]
通讯作者: Otagiri M.
共 24 条
    Development of novel hybrid anti-oxidant based on albumin fusion technology and its therapeutic application on acute radiation syndrome
    • 批准号:
      15K15008
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2015
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    Construction of an Innovative Bone Marrow Delivery System of Anticancer Drug for Control of Malignant Tumors' Bone Metastasis
    • 批准号:
      25670085
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.5万
    • 财政年份:
      2013
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    Design and Evaluation of Next Generation Albumin-thioredoxin Fusion Protein for Multiple Organ Failure Treatment
    • 批准号:
      24390043
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.06万
    • 财政年份:
      2012
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    Development of effective blood purification treatment method usingHSA bound toxic comnpodus designed bpyhase display tecnohlogy
    • 批准号:
      23659088
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2011
    • 负责人:
      OTAGIRI Masaki
    • 依托单位:
    海外基金